Ryan M Fryer

Summary

Affiliation: Abbott Laboratories
Country: USA

Publications

  1. ncbi request reprint Effects of intravenous ABT-870 (iron (III)-hydroxide oligosaccharide) on mean arterial pressure and heart rate in the anaesthetized beagle: comparison with other iron-containing haematinic agents
    Lee C Preusser
    Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064 6119, USA
    Clin Exp Pharmacol Physiol 32:1020-6. 2005
  2. ncbi request reprint (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine
    Ryan M Fryer
    Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064 6119, USA
    J Cardiovasc Pharmacol 44:137-47. 2004
  3. doi request reprint ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats
    Patricia N Banfor
    Department of Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6119, USA
    J Cardiovasc Pharmacol 53:173-8. 2009
  4. ncbi request reprint Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs
    Patricia N Banfor
    Department of Integrative Pharmacology R46R, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Rd, Abbott Park, IL 60064 6119, USA
    Am J Physiol Heart Circ Physiol 294:H238-48. 2008
  5. doi request reprint Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and m
    Jason A Segreti
    Department of Integrative Pharmacology, R46R, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6119, USA
    J Pharmacol Exp Ther 325:331-40. 2008
  6. ncbi request reprint Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety
    John K Lynch
    Metabolic Disease Research, Integrative Pharmacology, Process Chemistry, and Exploratory Pharmacokinetics, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    J Med Chem 49:6569-84. 2006
  7. ncbi request reprint Pharmacological characterization of the novel dihydropyridine potassium channel opener, (9R)-9-(3-iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8(4H,7H)-dione (A-325100), and the regulation of cardiovascular function in conscious
    Ryan M Fryer
    Department of Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064 6119, USA
    J Cardiovasc Pharmacol 46:232-40. 2005
  8. ncbi request reprint Systemic activation of the calcium sensing receptor produces acute effects on vascular tone and circulatory function in uremic and normal rats: focus on central versus peripheral control of vascular tone and blood pressure by cinacalcet
    Ryan M Fryer
    Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6119, USA
    J Pharmacol Exp Ther 323:217-26. 2007
  9. ncbi request reprint Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibi
    Zhonghua Pei
    Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6098, USA
    J Med Chem 49:6439-42. 2006
  10. doi request reprint Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growt
    Pamela H Franklin
    Department of Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6119, USA
    J Pharmacol Exp Ther 329:928-37. 2009

Detail Information

Publications25

  1. ncbi request reprint Effects of intravenous ABT-870 (iron (III)-hydroxide oligosaccharide) on mean arterial pressure and heart rate in the anaesthetized beagle: comparison with other iron-containing haematinic agents
    Lee C Preusser
    Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064 6119, USA
    Clin Exp Pharmacol Physiol 32:1020-6. 2005
    ..These data demonstrate that ABT-870 may have a substantial therapeutic window and considerable clinical potential for iron-replacement therapy...
  2. ncbi request reprint (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine
    Ryan M Fryer
    Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064 6119, USA
    J Cardiovasc Pharmacol 44:137-47. 2004
    ..These data suggest that A-278637 possesses a greater functional selectivity for urinary bladder versus vascular smooth muscle in vivo and that A-278637 may exhibit a more favorable therapeutic index than either ZD-6169 or WAY-133537...
  3. doi request reprint ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats
    Patricia N Banfor
    Department of Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6119, USA
    J Cardiovasc Pharmacol 53:173-8. 2009
    ..Thus, ETA receptor blockade effectively alleviated hypertension with RTK inhibition and may serve a dual therapeutic role by preventing hypertension and slowing tumor progression...
  4. ncbi request reprint Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs
    Patricia N Banfor
    Department of Integrative Pharmacology R46R, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Rd, Abbott Park, IL 60064 6119, USA
    Am J Physiol Heart Circ Physiol 294:H238-48. 2008
    ....
  5. doi request reprint Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and m
    Jason A Segreti
    Department of Integrative Pharmacology, R46R, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6119, USA
    J Pharmacol Exp Ther 325:331-40. 2008
    ....
  6. ncbi request reprint Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety
    John K Lynch
    Metabolic Disease Research, Integrative Pharmacology, Process Chemistry, and Exploratory Pharmacokinetics, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    J Med Chem 49:6569-84. 2006
    ..However, this analogue also led to prolongation of the QT interval in the dog that was linked to affinity for hERG channel and unexpectedly potent functional blockade of this ion channel...
  7. ncbi request reprint Pharmacological characterization of the novel dihydropyridine potassium channel opener, (9R)-9-(3-iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8(4H,7H)-dione (A-325100), and the regulation of cardiovascular function in conscious
    Ryan M Fryer
    Department of Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064 6119, USA
    J Cardiovasc Pharmacol 46:232-40. 2005
    ..Thus, these data demonstrate that the hemodynamic effects of vasoactive compounds, such as KCOs, can be effectively profiled in both the conscious and anesthetized dog...
  8. ncbi request reprint Systemic activation of the calcium sensing receptor produces acute effects on vascular tone and circulatory function in uremic and normal rats: focus on central versus peripheral control of vascular tone and blood pressure by cinacalcet
    Ryan M Fryer
    Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6119, USA
    J Pharmacol Exp Ther 323:217-26. 2007
    ..Moreover, subsequent mechanistic studies suggest that increases in MAP produced by cinacalcet may be mediated by reduced tonic NO synthase-dependent NO production subsequent to reductions in blood iCa2+...
  9. ncbi request reprint Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibi
    Zhonghua Pei
    Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6098, USA
    J Med Chem 49:6439-42. 2006
    ..When dosed orally, 25 dose-dependently reduced glucose excursion in ZDF rats. Amide 25 is safe in a battery of in vitro and in vivo tests and may represent a new therapeutic agent for the treatment of type 2 diabetes...
  10. doi request reprint Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growt
    Pamela H Franklin
    Department of Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6119, USA
    J Pharmacol Exp Ther 329:928-37. 2009
    ..These studies demonstrate that the adverse cardiovascular effects of the VEGF/PDGF receptor tyrosine kinase inhibitor, ABT-869, are readily controlled by conventional antihypertensive therapy without affecting antitumor efficacy...
  11. ncbi request reprint Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists
    Robert J Altenbach
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064 6123, USA
    J Med Chem 50:5439-48. 2007
    ..Further studies on the pharmaceutic properties of this series of quinolines discovered a potential problem with photochemical instability, an issue which contributed to the discontinuation of this series from further development...
  12. ncbi request reprint Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice
    Ryan M Fryer
    Integrative Pharmacology, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6119, USA
    Nephron Physiol 106:p76-81. 2007
    ..Vitamin D receptor activators (VDRAs) may suppress renin expression and VDR-mediated renin inhibitors may offer a novel mechanism to control the RAS...
  13. ncbi request reprint Blood pressure regulation by ETA and ETB receptors in conscious, telemetry-instrumented mice and role of ETA in hypertension produced by selective ETB blockade
    Ryan M Fryer
    Department of Integrative Pharmacology, R46R, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Rd, Abbott Park, IL 60064 6119, USA
    Am J Physiol Heart Circ Physiol 290:H2554-9. 2006
    ....
  14. doi request reprint Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia
    Prisca Honore
    Abbott Laboratories, Abbott Park, IL 60064, USA
    Pain 142:27-35. 2009
    ..The analgesic efficacy of ABT-102 supports its advancement into clinical studies...
  15. ncbi request reprint Cardiovascular disease in chronic kidney failure: the role of VDR activators
    J Ruth Wu-Wong
    Curr Opin Investig Drugs 7:206-13. 2006
    ..In this review, we discuss recent preclinical and clinical data regarding the role of VDR and its ligands in the cardiovascular system...
  16. doi request reprint Antagonism of TRPV1 receptors indirectly modulates activity of thermoregulatory neurons in the medial preoptic area of rats
    Steve McGaraughty
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, R4PM, AP9 1, 100 Abbott Park Road, Abbott Park, IL 60064 6118, USA
    Brain Res 1268:58-67. 2009
    ..These data demonstrate that antagonist block of abdominal TRPV1 receptors indirectly modulates activity of thermoregulatory neurons in the mPOA in a manner that is consistent with producing an acute rise in body temperature...
  17. doi request reprint Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties
    Karin R Tietje
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    CNS Neurosci Ther 14:65-82. 2008
    ....
  18. ncbi request reprint Predictive, non-GLP models of secondary pharmacodynamics: putting the best compounds forward
    Glenn A Reinhart
    Dept R46R, Bldg AP9, Abbott Laboratories, Abbott Park, IL 60064 6119, USA
    Curr Opin Chem Biol 9:392-9. 2005
    ....
  19. ncbi request reprint Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the tr
    David J Madar
    Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064 6001, USA
    J Med Chem 49:6416-20. 2006
    ..0 nM) and selective (Ki(DPP8) > 30 microM; Ki(DPP9) > 30 microM) clinical candidate, ABT-279, that is orally available, efficacious, and remarkably safe in preclinical safety studies...
  20. ncbi request reprint Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists
    Philip R Kym
    Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA
    J Med Chem 49:2339-52. 2006
    ....
  21. ncbi request reprint Histamine in cardiac sympathetic ganglia: a novel neurotransmitter?
    Ryan M Fryer
    Department of Integrative Pharmacology, Abbott Laboratories, Abott Park, IL 60064 6119, USA
    Mol Interv 6:14-9, 2. 2006
    ..Although histamine does elicit many effects in the heart, does it stand up to rigorous scrutiny and fulfill certain criteria that are used to define neurotransmitters?..
  22. pmc Reduced heart size and increased myocardial fuel substrate oxidation in ACC2 mutant mice
    M Faadiel Essop
    Department of Physiological Sciences, Stellenbosch University, Stellenbosch, South Africa
    Am J Physiol Heart Circ Physiol 295:H256-65. 2008
    ....
  23. ncbi request reprint Delta opioid agonists and volatile anesthetics facilitate cardioprotection via potentiation of K(ATP) channel opening
    Hemal H Patel
    Medical College of Wisconsin, Department of Pharmacology and Toxicology, Milwaukee, Wisconsin 53226, USA
    FASEB J 16:1468-70. 2002
    ..To date, this is the first demonstration that opioids and volatile anesthetics work in conjunction to confer protection against myocardial infarction through potentiation of cardiac K(ATP) channel opening...
  24. ncbi request reprint 12-lipoxygenase in opioid-induced delayed cardioprotection: gene array, mass spectrometric, and pharmacological analyses
    Hemal H Patel
    Medical College of Wisconsin, Department of Pharmacology and Toxicology, 8701 Watertown Plank Rd, Milwaukee, WI 53226, USA
    Circ Res 92:676-82. 2003
    ..These data suggest that SNC-121 appears to enhance message and subsequently the activity and expression of 12-LO protein during times of stress, resulting in delayed cardioprotection...
  25. ncbi request reprint PKC-delta inhibition does not block preconditioning-induced preservation in mitochondrial ATP synthesis and infarct size reduction in rats
    Ryan M Fryer
    Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee 53226, USA
    Basic Res Cardiol 97:47-54. 2002
    ..These data suggest that PKC-delta does not play an important role in IPC and that differences in isoform importance are evident during pharmacological versus ischemia-induced preconditioning...